1 Ozempic is not FDA-approved for weight loss. Providers may, in their clinical discretion, prescribe it off-label if deemed appropriate for their patient. Wegovy® is the registered trademark of Novo Nordisk A/S.
2 Price includes medication only, if prescribed. An active Him & Hers Weight Loss Membership is required and fee not included ($39 for the first month, auto-renews at $149/month thereafter).
3 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy® oral semaglutide 25 mg (64 weeks) and about 1 in 3 taking Wegovy® injection 2.4 mg (68 weeks) lost ≥20% of body weight, alongside diet and exercise. Average weight loss was approximately 14–15%. Individual results may vary. Stopping treatment may result in weight regain.
4 Price includes membership fee only ($39 for the first month, auto-renews at $149/month thereafter). Billed separately and does not include or guarantee a prescription. Medication is not available without a membership.
5 FSA & HSA eligibility and coverage vary by plan provider.
6 For adults with heart disease and obesity or overweight, along with a reduced-calorie diet and increased physical activity.
Disclaimers
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, including the diversity, efficacy, pricing and dosages thereof, statements regarding our weight management program, statements regarding the membership model, including pricing thereof and what it is expected to include, and statements regarding the broader health impacts of GLP-1s. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the semaglutide offerings available on our platform (branded and compounded), and the related customer response; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options available on our platform; risks related to our international expansion efforts, including any pending or completed acquisitions, and the timing, integration and performance thereof; changes in the application, interpretation, and enforcement of healthcare, consumer protection or privacy laws or regulations applicable to our business; the timing, outcome or impact of this announcement on ongoing litigation, governmental actions or regulatory statements; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. In addition, at this time we cannot predict or estimate the impact any collaboration with Novo Nordisk and / or the impact any shift in our GLP-1 business may have on our future results, including revenue or EBITDA.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of March 26, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.